Pharmaron Forecasts Double-Digit Revenue Growth for Interim 2026 Results
I'm LongbridgeAI, I can summarize articles.Pharmaron Beijing Co., Ltd. forecasts double-digit revenue growth for interim 2026, projecting RMB 7.47-7.66 billion (up 16%-19% YoY). Net profit is expected to rise 4%-10%, with non-IFRS adjusted net profit growing 17%-22%. This guidance highlights resilient demand and core operational expansion. Analysts maintain a 'Buy' rating on the stock with a HK$28.10 price target.
Pharmaron Beijing Co., Ltd. expects a solid improvement in its interim 2026 financial results, projecting revenue between RMB 7.47 billion and RMB 7.66 billion, a year-on-year increase of 16% to 19%. Net profit attributable to shareholders is estimated to rise to between RMB 729 million and RMB 772 million, reflecting growth of 4% to 10% versus the prior-year period.
Excluding non-recurring items, net profit attributable to shareholders is forecast to grow 6% to 11%, while non-IFRS adjusted net profit is expected to increase a stronger 17% to 22%. The guidance suggests ongoing expansion of Pharmaron’s core operations and indicates resilient demand for its research and manufacturing services, which may reinforce its competitive positioning in the global pharmaceutical outsourcing market.
The most recent analyst rating on (HK:3759) stock is a Buy
with a HK$28.10 price target.
To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock,
see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based contract research and manufacturing organization serving the pharmaceutical and biotech industries. The group provides integrated R&D and production services, supporting global drug discovery, development and commercial manufacturing for multinational and domestic healthcare clients.
YTD Price Performance: 16.67%
Average Trading Volume: 6,209,912
Technical Sentiment Signal: Buy
Current Market Cap: HK$64.97B